The complaint, filed by the law firm Hagens Berman, targets the period between April 16, 2025, and May 4, 2026. Investors allege that GeneDx management painted an overly optimistic picture of its growth trajectory, specifically touting the strategic importance of Fabric Genomics, which the company acquired for $33.2 million in cash. By the following year, however, the narrative shifted abruptly when GeneDx reported a $31.2 million impairment charge on the unit—effectively writing off 94% of the acquisition's value.
GeneDx Faces Shareholder Lawsuit Following Fabric Genomics Write-off
A 49% stock price collapse on May 5, 2026, has triggered a securities class action against GeneDx Holdings. The lawsuit centers on allegations that the diagnostics firm misled investors regarding the value of its Fabric Genomics acquisition and the stability of its core financial performance metrics during the previous fiscal year.
Financial disclosures revealed that the company’s average reimbursement rate failed to meet the projections management provided as recently as February 2026. This decline was attributed to an adverse shift in product mix toward genome testing, which carries significantly lower margins than exome tests. Consequently, GeneDx slashed its 2026 revenue guidance by 12%. Reed Kathrein, the Hagens Berman partner overseeing the investigation, stated the firm is examining whether management intentionally obscured the true value of the acquired software unit and the underlying volatility in its testing business. Investors seeking to participate in the class action have until August 3, 2026, to file as lead plaintiffs.
Comments (0)
No comments yet. Be the first!